A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of TB006 in Participants with Parkinson's Disease
Latest Information Update: 28 Apr 2026
At a glance
- Drugs TB 006 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors TrueBinding
Most Recent Events
- 23 Apr 2026 Planned End Date changed from 1 Mar 2026 to 28 Nov 2026.
- 23 Apr 2026 Planned primary completion date changed from 1 Mar 2026 to 28 Nov 2026.
- 23 Apr 2026 Status changed from recruiting to active, no longer recruiting.